June 28, 2018 05:49 PM EDT

Finally, Celgene wins. Anemia drug luspatercept — partnered with Acceleron — scores in PhIII trial

Brittany Meiling

After Celgene’s many trips and blunders this year, the pharma giant might finally please investors Thursday with cheery news from one of its late-stage blockbuster …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Finally, Celgene wins. Anemia drug luspatercept — partnered with Acceleron — scores in PhIII trial

Brittany Meiling

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

US warns drugmakers against misrepresenting cost of imported products

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Fi­nal­ly, Cel­gene wins. Ane­mia drug lus­pa­ter­cept — part­nered with Ac­celeron — scores in PhI­II tri­al

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Finally, Celgene wins. Anemia drug luspatercept — partnered with Acceleron — scores in PhIII trial